VCM
ARQT icon

Voleon Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Voleon Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.91M Sell
123,683
-52,917
-30% -$1.35M 0.06% 279
2025
Q4 		$5.13M Buy
176,600
+151,765
+611% +$3.89M 0.11% 200
2025
Q3 		$468K Buy
+24,835
New +$392K 0.01% 602

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Voleon Capital Management's ARQT Position: Q1 2026 in Review

Voleon Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 30% in Q1 2026, selling an estimated $1.35M and leaving 123,683 shares worth $2.91M. The position accounts for 0.06% of the portfolio, ranked #279.

Voleon Capital Management first reported a position in ARQT in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.13M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Voleon Capital Management held 123,683 shares of Arcutis Biotherapeutics worth $2.91M as of Q1 2026.
  • Voleon Capital Management sold 52,917 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.35M.
  • Arcutis Biotherapeutics made up 0.06% of Voleon Capital Management's portfolio in Q1 2026, its #279 holding.
  • Voleon Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Arcutis Biotherapeutics position peaked at $5.13M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.